Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Menarini launches anti-anginal Ranexa in UK and Germany

This article was originally published in Scrip

Executive Summary

CV Therapeutics and Menarini have launched their first-in class anti-anginal Ranexa (ranolazine extended-release tablets) in the UK and Germany, as an adjunctive therapy for patients with stable angina pectoris that are inadequately controlled or intolerant to first-line therapies.

You may also be interested in...



P&G to co-promote Somaxon's Silenor in the US

Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.

GSK's shingles vaccine begins Phase III studies

GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.

Optimer's fidaxomicin filing accepted in EU

The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.

Topics

Related Companies

UsernamePublicRestriction

Register

AP007430

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel